European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Union Urges Court to Compel Trump Administration to Restore CFPB Funding 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
Appeals Court Blocks Expansion of Fast-Track Deportations in the U.S. 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Tabletop particle accelerator could transform medicine and materials science 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Singapore Court Allows $2.7 Billion 1MDB Lawsuit Against Standard Chartered to Proceed 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
